biotin has been researched along with 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid in 14 studies
| Studies (biotin) | Trials (biotin) | Recent Studies (post-2010) (biotin) | Studies (1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid) | Trials (1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid) | Recent Studies (post-2010) (1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid) |
|---|---|---|---|---|---|
| 14,847 | 95 | 3,882 | 792 | 16 | 476 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Hnatowich, DJ; Virzi, F; Wu, C | 1 |
| Axworthy, DB; Brechbiel, MW; Carrasquillo, JA; Garmestani, K; Goldman, CK; Mallett, RW; Theodore, LJ; Waldmann, TA; Yao, Z; Zhang, M; Zhang, Z | 1 |
| Chelli, M; Chinol, M; De Luca, A; Ginanneschi, M; Leone, G; Paganelli, G; Papi, S; Papini, AM; Sabatino, G | 1 |
| Mårtensson, L; Nilsson, R; Ohlsson, T; Senter, P; Sjögren, HO; Strand, SE; Tennvall, J; Wang, Z | 1 |
| Bendahl, PO; Lindgren, L; Mårtensson, L; Nilsson, R; Ohlsson, T; Sjögren, HO; Strand, SE; Tennvall, J; Wang, Z | 1 |
| Chinol, M; Choi, S; De Santis, R; Ferrari, L; Ginanneschi, M; Lindstedt, R; Pace, S; Paganelli, G; Papi, S; Urbano, N | 1 |
| Mårtensson, L; Nilsson, R; Ohlsson, T; Sjögren, HO; Strand, SE; Tennvall, J | 1 |
| Blom, E; Långström, B; Velikyan, I | 1 |
| Aita, K; Kuge, Y; Saji, H; Seki, K; Shimizu, Y; Temma, T | 1 |
| Parameswarappa, SG; Pigge, FC; Schultz, MK | 1 |
| Buchegger, F; Chyan, MK; Hamlin, DK; Lin, Y; Pagel, JM; Pantelias, A; Park, SI; Press, OW; Shenoi, J; Wan, F; Wilbur, DS; Wilbur, SM | 1 |
| Bartoli, M; Carollo, A; Chinol, M; Frediani, M; Ginanneschi, M; Lumini, M; Melani, F; Messori, L; Paganelli, G; Papini, AM; Petrucci, G; Pratesi, A; Rosi, L | 1 |
| Appelhans, D; Boye, S; Daeg, J; Janke, A; Lederer, A; Shi, X; Temme, A; Voit, B; Xu, X; Zhao, J; Zhao, L | 1 |
| Axworthy, DB; Cheal, SM; Cheung, NV; Guo, HF; Larson, SM; Ouerfelli, O; Patel, M; Veach, D; Xu, H; Yang, G; Zanzonico, PB | 1 |
14 other study(ies) available for biotin and 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
| Article | Year |
|---|---|
Investigations of N-linked macrocycles for 111In and 90Y labeling of proteins.
Topics: Amines; Animals; Avidin; Biotin; Chelating Agents; Drug Stability; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Indium Radioisotopes; Mice; Pentetic Acid; Proteins; Tissue Distribution; Yttrium Radioisotopes | 1992 |
Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213.
Topics: Alpha Particles; Animals; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biotin; Bismuth; Heterocyclic Compounds, 1-Ring; Leukemia-Lymphoma, Adult T-Cell; Mice; Mice, Inbred NOD; Neoplasms, Experimental; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Receptors, Interleukin-2; Streptavidin; Survival Rate; Treatment Outcome | 2002 |
A new biotin derivative-DOTA conjugate as a candidate for pretargeted diagnosis and therapy of tumors.
Topics: Antineoplastic Agents; Avidin; Biotin; Chelating Agents; Drug Stability; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Neoplasms; Protein Binding; Radiopharmaceuticals; Yttrium | 2003 |
Determining maximal tolerable dose of the monoclonal antibody BR96 labeled with 90Y or 177Lu in rats: establishment of a syngeneic tumor model to evaluate means to improve radioimmunotherapy.
Topics: Animals; Antibodies, Monoclonal; Biotin; Body Weight; Brain; Chelating Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Heterocyclic Compounds, 1-Ring; Leukocytes; Lutetium; Maximum Tolerated Dose; Platelet Count; Radioimmunotherapy; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Rats; Time Factors; Yttrium Radioisotopes | 2005 |
Blood pharmacokinetics of various monoclonal antibodies labeled with a new trifunctional chelating reagent for simultaneous conjugation with 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid and biotin before radiolabeling.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Avidin; Biotin; Chelating Agents; Doxorubicin; Heterocyclic Compounds, 1-Ring; Immunoconjugates; Immunoglobulin G; Quality Control; Radioimmunodetection; Radioimmunotherapy; Radioisotopes; Rats; Rituximab; Time Factors; Trastuzumab | 2005 |
Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT).
Topics: Animals; Antibodies, Monoclonal; Biotin; Drug Delivery Systems; Drug Evaluation, Preclinical; Heterocyclic Compounds, 1-Ring; Isotope Labeling; Male; Metabolic Clearance Rate; Mice; Mice, Inbred C57BL; Organ Specificity; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Tissue Distribution | 2007 |
Improved tumor targeting and decreased normal tissue accumulation through extracorporeal affinity adsorption in a two-step pretargeting strategy.
Topics: Adsorption; Animals; Biotin; Colonic Neoplasms; Extracorporeal Circulation; Heterocyclic Compounds, 1-Ring; Indium Radioisotopes; Liver; Lymph Nodes; Organometallic Compounds; Pancreas; Radionuclide Imaging; Rats; Rats, Inbred BN; Streptavidin; Tissue Distribution | 2007 |
68Ga-labeling of biotin analogues and their characterization.
Topics: Alkanes; Avidin; Biotin; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Polyethylene Glycols; Protein Stability; Staining and Labeling | 2009 |
Synthesis of a new NIR fluorescent Nd complex labeling agent.
Topics: Animals; Avidin; Biological Transport; Biotin; Cell Line, Tumor; Fluorescent Dyes; Heterocyclic Compounds, 1-Ring; Infrared Rays; Maleimides; Neodymium; Organometallic Compounds; Rats; Spectrometry, Fluorescence | 2010 |
Synthesis of a DOTA--biotin conjugate for radionuclide chelation via Cu-free click chemistry.
Topics: Biotin; Chelating Agents; Cyclooctanes; Heterocyclic Compounds, 1-Ring; Molecular Structure; Radiopharmaceuticals | 2010 |
Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants.
Topics: Acetylgalactosamine; Animals; Antigens, CD20; Biotin; Cell Line, Tumor; Chelating Agents; Drug Design; Heterocyclic Compounds, 1-Ring; Humans; Lymphoma, B-Cell; Mice; Molecular Structure; Mutation; Recombinant Fusion Proteins; Single-Chain Antibodies; Streptavidin; Xenograft Model Antitumor Assays | 2010 |
Design and solid phase synthesis of new DOTA conjugated (+)-biotin dimers planned to develop molecular weight-tuned avidin oligomers.
Topics: Avidin; Biotin; Dimerization; Drug Design; Drug Stability; Heterocyclic Compounds, 1-Ring; Isotope Labeling; Models, Molecular; Molecular Weight; Protein Multimerization; Protein Structure, Quaternary; Solid-Phase Synthesis Techniques | 2015 |
Bivalent Peptide- and Chelator-Containing Bioconjugates as Toolbox Components for Personalized Nanomedicine.
Topics: Animals; Antigens, Surface; Avidin; Biotin; Chelating Agents; Contrast Media; Dendrimers; Diagnostic Imaging; ErbB Receptors; Folic Acid; Glutamate Carboxypeptidase II; HEK293 Cells; Heterocyclic Compounds, 1-Ring; Humans; Male; Mice, Inbred BALB C; Molecular Targeted Therapy; Nanomedicine; Peptides; Polyethylene Glycols; Prostatic Neoplasms; Xenograft Model Antitumor Assays | 2020 |
An
Topics: Acetylgalactosamine; Animals; Biotin; Cell Line, Tumor; Colorectal Neoplasms; Dendrimers; Haptens; Heterocyclic Compounds, 1-Ring; Humans; Immunoconjugates; Mice; Radioimmunotherapy; Tissue Distribution; Xenograft Model Antitumor Assays | 2020 |